+$883.8M
Net Activity
Institutions Holding
278
Popularity Rank
#2139
Avg Weight
0.46%
Total Value
$5.8B
278 institutions currently hold CELC, with 166 net buyers and 110 net sellers this quarter.
Institutional Moves (Q1 2026)
Majority Increased
Based on recent trading activity
Net Selling Institutions
110
Net Buying Institutions
166
Top 5 by Value
+$2.4B
Total Buy Value
$2.2B
Total Sell Value
166
Net Buyers
110
Net Sellers
2
Filings (90d)
$317.75M
Total Est. Value
3.10M shares
Planned Shares
| Filer | Filing Date | Est. Value |
|---|---|---|
| 667, L.P. | 2026-07-14 | $26.79M |
| Baker Brothers Life Sciences, L.P. | 2026-07-14 | $290.96M |
Form 144 is a planned sale notice, not an executed transaction. Form 144 Tracker。
No Schedule 13D/13G filings for this ticker
2
Filings (14d)
On July 14, 2026, Celcuity Inc. announced that the U.S. FDA approved REVTORPYK (gedatolisib) for treating patients with HR+/HER2- locally advanced or metastatic breast cancer who do not have a PIK3CA mutation. The company disclosed this in an 8-K filing.
View Full Filing (SEC EDGAR)Celcuity Inc. filed an amendment (Form 8-K/A) to a previously submitted Current Report. The amendment is dated July 14, 2026, but the provided excerpt does not include the revised disclosure. Based on the filed information, this is a routine procedural filing without new material events.
View Full Filing (SEC EDGAR)The most-added stocks by 13F institutions this quarter
Institutions Holding
6,150
Total reported value
$2.1T
3245 13F institutions increased their position this quarter
Institutions Holding
5,957
Total reported value
$1.5T
3028 13F institutions increased their position this quarter
Institutions Holding
5,764
Total reported value
$3.0T
2743 13F institutions increased their position this quarter